Cobimetinib is a highly selective MEK inhibitor that was approved in combination with vemurafenib in 2015 for the treatment of patients with unresectable or metastatic BRAF V600E/V600K-mutated melanoma [128]. The gene discussed is BRAF; the disease is melanoma.